Citations

Clear

1794 citation(s) found for "Yu, Stephanie".

Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study.
Heerema, Nyla A. , Byrd, John C. , Cin, Paola Dal , Aquila, Marie L. Dell’, Koduru, Prasad , Aviram, Ayala, Smoley, Stephanie A., Rassenti, Laura Z., Greaves, Andrew, Brown, Jennifer R. , Rai, Kanti R, Dyke, Daniel Van, Rai, Kanti R, Kipps, Thomas J. , Kay, Neil E. , Dyke, Daniel L. Van

Mayo Clinic

Blood | October 9, 2019 | Volume: 114 | Issue: 22 | Pages: 1614-1614

10.1182/blood.v114.22.1614.1614 Get It

Abstract Abstract 1614 Poster Board I-640 Background Cytogenetic abnormalities in B-cell CLL are important prognostic indicators for predicting disease progression and treatment response. Until recently, only interphase cytogenetics has been readily applicable to clinical use in CLL due to the inability of traditional mitogens to promote effective metaphase cytogenetic identification. Recently, cytokine or CpG oligonucleotide stimulation has been utilized to promote efficient metaphase analysis. One concern with this approach is the actual clonality and reproducibility of such clones when examined by different cytogenetic laboratories. The CLL Research Consortium (CRC) conducted a prospective trial to test (1) whether CpG would enhance detection of abnormal clones and (2) whether the CRC cytogenetic laboratories would achieve similar results when testing the same patient samples. Methods Initially, one laboratory compared stimulation of CLL cells using CpG versus pokeweed mitogen (PWM) + 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in the same samples. To test the reproducibility of CpG stimulation, fresh blood samples from 1 normal control and 12 CLL patients were collected at one site and distributed (blinded to phenotype and prior cytogenetic results) to 5 CRC cytogenetic laboratories where they were cultured for 3 days using CpG stimulation, harvested, banded and analyzed utilizing standard laboratory procedures. When possible, each laboratory analyzed 20 metaphases per case. Interphase FISH analysis for CLL (including probes for chromosomes 6q, 11q, 12, 13q, 17p, and IGH/CCND1) was also done on each sample. Results In the PWM+TPA versus CpG comparison, more cases were found to have clonal abnormalities with CpG stimulation (147 of 229, 64%) than with PWM+TPA (110 of 229, 48%; P=0.0005). All clonal abnormalities detected in the PWM+TPA cultures were also observed in the CpG cultures. In the 5-laboratory CpG comparison, the results were compiled and compared to the concurrent FISH results. The CpG karyotypes were concordant with the FISH results. The control case had a normal CpG-stimulated karyotype in all 5 laboratories. Three cases exhibited a complex karyotype; one of these also exhibited 11q-, one had 17p-, and one had neither. The cytogenetic descriptions varied modestly among labs, but all identified the complex clones. Every case including the control exhibited some nonclonal abnormal cells, but no pattern was detected among the 5 labs. When an abnormal clone was found by only 1 or 2 labs, it was present in only a very small number of cells. A small 13q- clone was observed in 2 cases in 1 and 2 labs (3 of 20 and 5 of 50 cells, respectively), and was confirmed by interphase FISH. A single lab found 2 of 30 cells with a t(12;15) in one case. Conclusions Abnormal clones in CLL are more readily detected with CpG stimulation than with traditional B-cell mitogens. The clonal abnormalities revealed by CpG stimulation are consistent with the “gold standard” interphase FISH results, and are reproducible among different cytogenetic laboratories. We have no evidence that CpG oligonucleotides create new clonal B-cell populations in vitro during 3 days of cell culture. CpG stimulation in vitro reveals clonal cytogenetic abnormalities and complexity in CLL that should be evaluated as potential independent prognostic parameters. Disclosures Kay: Biogenc-Idec, Celgene, Genentech, genmab: Membership on an entity's Board of Directors or advisory committees; Genentech, Celgene, Hospira, Polyphenon Pharma, Sanofi-Aventis: Research Funding.
Evaluation of a Novel Wellness Assessment Device (Preventiometer): A Feasibility Pilot Study
Nanda, S. , Mahapatra, Saswati , Lindeen, Stephanie A. , Bernau, Joleen L, Cutshall, Susanne M. , Schierwater, Bernd , Chon, Tony Y. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , Nanda, Sanjeev , Wahner-Roedler, Dietlind L

Mayo Clinic

Global Advances in Health and Medicine | October 9, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119881096 | PMID 31637111 Get It

Background Periodic wellness assessments can provide an estimate of a person’s relative risks for major diseases, but wellness visits are underused. Our suggestion is to use a comprehensive device during a single visit. Objective The goal of this pilot study was to evaluate the feasibility of a novel one-stop wellness device (Preventiometer; iPEx5 GmbH, Greifswald, Germany) for performing multiple tests and providing a comprehensive wellness assessment in a short period. Methods A Preventiometer was used to provide wellness assessments for 10 healthy volunteers who then answered a 25-question survey to rate their satisfaction with the testing and their overall impression. Results All volunteers agreed or strongly agreed with the following: The assessment reports were easy to understand, the Preventiometer met their satisfaction, the participants were comfortable during the assessment, and all measurements and testing were well coordinated. Participants liked the instant test result feature. Most (90%) agreed that the machine was useful for a quick health assessment for busy people, and 70% felt that it was time efficient. Conclusion In this feasibility pilot study, the Preventiometer performed multiple tasks and provided a comprehensive wellness assessment in a short period. Participants reported remarkably high satisfaction with the tests. A larger study is needed to prove that this is a pragmatic approach to help individuals improve their health.
Clinical spectrum of individuals with pathogenic N F1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1
Koczkowska, Magdalena , Callens, Tom, Chen, Yunjia , Gomes, Alicia , Hicks, Alesha D., Sharp, Angela, Johns, Eric, Uhas, Kim, Armstrong, Linlea , Bosanko, Katherine A. , Babovic‐Vuksanovic, Dusica , Baker, Laura, Basel, Donald , Bengala, Mario, Chambers, Chelsea , Clarkson, L. Kate, Clementi, Maurizio , Cortés, Fanny, Cunningham, Mitch , D’Agostino, Daniela , Delatycki, Martin B. , Digilio, M. Cristina , Dosa, Laura, Esposito, Silvia , Freckmann, Mary‐Louise , Fauth, Christine , Giugliano, Teresa , Giustini, Sandra , Goetsch, Allison L. , Goldberg, Yael , Greenwood, Robert , Griffis, Cristin, Gripp, Karen W. , Gupta, Punita , Haan, Eric , Hachen, Rachel K., Haygarth, Tamara L., Hernández‐Chico, Concepción, Hodge, Katelyn, Hopkin, Robert J. , Hudgins, Louanne , Janssens, Sandra , Keller, Kory, Kelly‐Mancuso, Geraldine, Kochhar, Aaina , Korf, Bruce R. , Lewis, Andrea M. , Liebelt, Jan, Lichty, Angie, Listernick, Robert , Lyons, Michael J. , Maystadt, Isabelle , Ojeda, Mayra Martinez, McDougall, Carey, McGregor, Lesley , Melis, Daniela , Mendelsohn, Nancy J., Nowaczyk, Małgorzata J.M. , Ortenberg, June, Panzer, Karin, Pappas, John , Pierpont, Mary Ella , Pinna, Valentina, Pivnick, Enikö K., Pond, Dinel , Powell, Cynthia M. , Rogers, Caleb , Ruhrman‐Shahar, Noa , Rutledge, S. Lane , Saletti, Veronica , Sandaradura, Sarah A. , Schatz, Ulrich A. , Schreiber, Allison, Sellars, Elizabeth A. , Siqveland, Elizabeth, Slopis, John M. , Smith, Rosemarie, Spalice, Alberto , Stockton, David W., Streff, Haley , Theos, Amy , Tran, Grace , Trapane, Pamela , Trevisson, Eva , Ullrich, Nicole J. , Ende, Jenneke van den , Wallace, Stephanie E , Weaver, David D. , Yohay, Kaleb , Zackai, Elaine H. , Zonana, Jonathan, Zurcher, Vickie, Claes, Kathleen , Eoli, Marica , Wimmer, Katharina , Luca, Alessandro De , Messiaen, Ludwine , Trevisson, Eva , Wangler, Michael F , Claes, Kathleen B M , Wimmer, Katharina , De Luca, Alessandro , Messiaen, Ludwine M , Gupta, Punita , Bennett, James T , Fox, Stephanie, Hernández-Chico, Concepción, Piluso, Giulio , Santoro, Claudia , Scott, Daryl A , Sheffer, Ruth N. , Tomlinson, Gail Elizabeth , Vergano, Samantha A. Schrier , Martín, Yolanda , Legius, Eric

Mayo Clinic

Human Mutation | October 9, 2019 | Volume: 41 | Issue: 1 | Pages: 299-315

10.1002/humu.23929 | PMID 31595648 Get It

1654 An Unusual Colon Lesion: Colon Metastasis From Primary Lung Adenocarcinoma
Meade, Charles , Hansel, Stephanie L.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S923-S924

10.14309/01.ajg.0000596144.06597.68 Get It

INTRODUCTION: Primary lung cancers infrequently metastasize to the gastrointestinal tract. We describe one case of isolated colonic metastasis identified at diagnosis of the primary lung malignancy and the associated immunohistochemical pattern. CASE DESCRIPTION/METHODS: An 80-year-old man presented for evaluation of subacute onset shortness of breath. CT imaging showed a spiculated mass with associated ipsilateral intrathoracic lymphadenopathy. PET-CT was performed for staging and revealed a hypermetabolic focus in the left colon with recommendation for follow up colonoscopy. No other significant lesions or evidence of distant metastatic disease were seen and subsequent biopsy of a subcarinal lymph node demonstrated primary pulmonary adenocarcinoma. The colonoscopy visualized a sessile 12 mm polyp in the recto-sigmoid colon (Figure 1). Prior colonoscopy within 5 years of presentation was normal. Colon polyp morphology showed moderately differentiated adenocarcinoma. Immunohistochemical staining of resected polyp was positive for TTF-1 and negative for CDX2. Oncology recommended tyrosine kinase inhibitor therapy for Stage IV disease and alectinib was initiated with good response at 6 month follow up. DISCUSSION: Non-small cell lung cancer metastatic to the colon is uncommon but can present as a spectrum from asymptomatic mucosal involvement to bulky obstructive disease. Autopsy series and published case reports suggest broad estimates of asymptomatic involvement in between 1-10% of lung primaries, with symptomatic gastrointestinal involvement in <1% of cases. 1 Endoscopic presentation of metastatic disease to the gastrointestinal tract is often non-characteristic and differentiating adenocarcinoma tissue of origin is aided by immunohistochemical staining. TTF-1 staining has been shown to be highly specific to pulmonary adenocarcinomas. 2 CDX2 expression is an important intestine-specific transcription factor, and CDX2 negativity suggests adenocarcinoma of non-GI origin. 3 Used in conjunction, distant metastatic disease to the GI tract can be identified.
540 Ergonomic and Procedural Metrics Associated With Musculoskeletal Pain Among Endoscopists
Miller, Alexander L. , Herberts, Michelle , Murray, Joseph, League, John, Chadrick, Hinson, Dyke, Carol Van, Miller, Alexander, Hansel, Stephanie L.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S312-S313

10.14309/01.ajg.0000591692.37323.9e Get It

INTRODUCTION: Rates of musculoskeletal (MSK) injury among gastroenterologists are estimated to be as high as 75%, exceeding rates of 35% among non-proceduralists. Specific ergonomic/procedural factors influencing these injuries have yet to be defined. We sought to characterize potential risk factors for MSK injury by analyzing the physical traits and technical procedural data of a cohort of endoscopists. METHODS: The QuickDASH (Disabilities of Arm, Shoulder, and Hand) survey was sent to all gastroenterologists across a large tertiary care system. Added questions assessed injury characteristics, glove size, and other demographic data. Endpoints defining affected vs. unaffected groups include self-reported function-limiting upper extremity or back pain, injury necessitating limiting/stopping endoscopy, and trends toward higher QuickDash, Work Impairment, or Sport/Instrument Disability scores. A procedural database capturing all endoscopic activities of each respondent from 2011 to 2018 was queried to gather procedural types, volumes, durations, and insertion times; scope types; and polyp detection rates. RESULTS: 64 surveys were completed (28.1% female, mean age 44.4 ±10.8 yrs). The average time in practice was 18.9 (±10.8) years. 51% (n = 33) of respondents reported significant activity-limiting pain, including hand/wrist (n = 31), arm/elbow (n = 12), shoulder (n = 19), and back (n = 24) pain. Characteristics between affected and non-affected groups are detailed in Table 1 with further exploratory analyses found in Table 2. Those needing to limit/stop endoscopy due to pain more frequently used pediatric scopes (31% vs. 19%, P = 0.037), took longer to perform colonoscopy (25.3 vs. 22.1 minutes, P = 0.035) and had lower yearly procedural volumes (532 vs. 807, P = 0.009). Those with hand/wrist pain had longer colonoscopy insertion times (9.35 vs. 8.21 minutes, P = 0.03) and less colonoscopy hands-on scope hours per year (81.2 vs. 111.7 hours, P = 0.039). Females had more severe shoulder pain ( P = 0.04), but there were no other associations with sex or small glove size. CONCLUSION: Activity-limiting MSK injuries affect over 50% of endoscopists. MSK symptoms were associated with longer procedure times and higher EGD or push enteroscopy volumes. Symptomatic subjects were more likely to use pediatric colonoscopes. Hand/wrist pain is the most common and (presumably) the most limiting type of injury. Further prospective monitoring is warranted to better elucidate which variables are causative versus compensatory responses to injury.
Evaluating a combined bowel preparation for small-bowel capsule endoscopy: a prospective randomized–controlled study
Alexander, Jeffrey A. , Bruining, David H. , Larson, Mark V., Mangan, Thomas F., Dierkhising, Ross , Almazar, Ann E., Rajan, Elizabeth , Hansel, Stephanie L. , Dierkhising, Ross A, Murray, Joseph A.

Mayo Clinic

Gastroenterology Report | October 4, 2019 | Volume: 8 | Issue: 1 | Pages: 31-35

10.1093/gastro/goz054 | PMID 32419949 Get It

Abstract Background Capsule endoscopy (CE) is frequently hindered by intra-luminal debris. Our aim was to determine whether a combination bowel preparation would improve small-bowel visualization, diagnostic yield, and the completion rate of CE. Methods Single-blind, prospective randomized–controlled study of outpatients scheduled for CE. Bowel-preparation subjects ingested 2 L of polyethylene glycol solution the night prior to CE, 5 mL simethicone and 5 mg metoclopramide 20 minutes prior to CE and laid in the right lateral position 30 minutes after swallowing CE. Controls had no solid food after 7 p.m. the night prior to CE and no liquids 4 hours prior to CE. Participants completed a satisfaction survey. Capsule readers completed a small-bowel-visualization assessment. Results Fifty patients were prospectively enrolled (56% female) with a median age of 54.4 years and 44 completed the study (23 patients in the control group and 21 in the preparation group). There was no significant difference between groups on quartile-based small-bowel visualization (all P &gt; 0.05). There was no significant difference between groups in diagnostic yield (P = 0.69), mean gastric (P = 0.10) or small-bowel transit time (P = 0.89). The small-bowel completion rate was significantly higher in the preparation group (100% vs 78%; P = 0.02). Bowel-preparation subjects reported significantly more discomfort than controls (62% vs 17%; P = 0.01). Conclusions Combined bowel preparation did not improve small-bowel visualization but did significantly increase patient discomfort. The CE completion rate improved in the preparation group but the diagnostic yield was unaffected. Based on our findings, a bowel preparation prior to CE does not appear to improve CE performance and results in decreased patient satisfaction (ClinicalTrials.gov, No. NCT01243736).
Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010–2015
Melkonian, Stephanie C. , Jim, Melissa A. , Haverkamp, Donald , Wiggins, Charles L. , McCollum, Jeffrey, White, Mary C. , Kaur, Judith S. , Espey, David K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 1, 2019 | Volume: 28 | Issue: 10 | Pages: 1604-1611

10.1158/1055-9965.epi-19-0288 | PMID 31575554 Get It

Abstract Background: Cancer incidence rates for American Indian and Alaska Native (AI/AN) populations vary by geographic region in the United States. The purpose of this study is to examine cancer incidence rates and trends in the AI/AN population compared with the non-Hispanic white population in the United States for the years 2010 to 2015. Methods: Cases diagnosed during 2010 to 2015 were identified from population-based cancer registries and linked with the Indian Health Service (IHS) patient registration databases to describe cancer incidence rates in non-Hispanic AI/AN persons compared with non-Hispanic whites (whites) living in IHS purchased/referred care delivery area counties. Age-adjusted rates were calculated for the 15 most common cancer sites, expressed per 100,000 per year. Incidence rates are presented overall as well as by region. Trends were estimated using joinpoint regression analyses. Results: Lung and colorectal cancer incidence rates were nearly 20% to 2.5 times higher in AI/AN males and nearly 20% to nearly 3 times higher in AI/AN females compared with whites in the Northern Plains, Southern Plains, Pacific Coast, and Alaska. Cancers of the liver, kidney, and stomach were significantly higher in the AI/AN compared with the white population in all regions. We observed more significant decreases in cancer incidence rates in the white population compared with the AI/AN population. Conclusions: Findings demonstrate the importance of examining cancer disparities between AI/AN and white populations. Disparities have widened for lung, female breast, and liver cancers. Impact: These findings highlight opportunities for targeted public health interventions to reduce AI/AN cancer incidence.
Dysphonia Due to Vocal Cord Injury After Rigid Bronchoscopy
Youssef, Stephanie J. , Orbelo, Diana M. , Sakata, Kenneth K. , Zimmermann, Terence M., Pittelko, Rebecca L. , Nelson, Darlene R. , Midthun, David E. , Edell, Eric S. , Ekbom, Dale C. , Orbelo, Diana

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | October 1, 2019 | Volume: 26 | Issue: 4 | Pages: e52-e55

10.1097/lbr.0000000000000587 | PMID 31569103 Get It

Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma
Skala, Stephanie L. , Ye, Jing C., Stumph, Jennifer , Macon, William R. , Quinones, Frances R, Khachaturov, Vadim, Dewar, Rajan , Skala, Stephanie L , Ye, Jing C., Ketterling, Rhett P.

Mayo Clinic

Clinical Pathology | September 30, 2019 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/2632010x19878410 | PMID 31633108 Get It

We report an index case of histiocytic sarcoma arising in a 70-year-old patient with long-standing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The patient presented in 2017 with painful, enlarging swelling of the left neck. He had remote history of cutaneous squamous cell carcinoma with no sign of recurrence, and his CLL/SLL was thought to be in remission. Computed tomography showed mild splenomegaly and multifocal lymphadenopathy including a 3-cm left neck mass. Biopsy of the left neck mass showed CLL/SLL with associated histiocytic sarcoma. Flow cytometry demonstrated a B cell neoplasm with CLL/SLL phenotype. Despite radiation therapy, he expired 3 months after presentation. Two similar cases (CLL/SLL and histiocytic sarcoma, follicular lymphoma and Langerhans cell sarcoma) from another institution are also illustrated. The pathological features of combined tumors in lymphoid neoplasms, a general framework to the work-up to determine interrelatedness of tumor components, and the clinical relevance are discussed.
Ten Eleven Things Not to Say to Your Female Colleagues
Borrero‐Mejias, Clarimar, Starling, Amaal J. , Burch, Rebecca , Loder, Elizabeth , Minen, Mia T. , Rastogi, Reena Gogia , Gautreaux, Jessica , Nahas, Stephanie J. , Monteith, Teshamae , Monteith, Teshamae S , Minen, Mia T , Metzler, Abby

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 26, 2019 | Volume: 59 | Issue: 10 | Pages: 1846-1854

10.1111/head.13647 | PMID 31557320 Get It